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Abstract: There is an accumulation of evidence that shows a significant role of cancer stem 
cells in tumor initiation, proliferation, relapse, and metastasis. Nanog is the most important core 
transcription marker of stem cells, known by its role in maintaining pluripotency, proliferation, 
and differentiation. Therefore, this study aimed to examine the role of Nanog in breast cancer 
cell tamoxifen resistance and its implications in breast cancer treatment. In this study, the 
expression of the three core transcription markers Nanog, Oct3/4, and Sox2 were quantitatively 
evaluated using flow cytometry. Then, small interfering RNA (siRNA) against human Nanog 
was transfected into tamoxifen-resistant breast cancer cells via Lipofectamine 2000. Nanog gene 
expression in the cells was detected using reverse transcription polymerase chain reaction (RT-
PCR). The change in cell proliferation was evaluated using the tetrazolium bromide method. An 
enzyme-linked immunosorbent assay was used to detect apoptosis of the transfected cells alone 
and in combination with 4-hydroxytamoxifen. The results showed a high level expression of 
Nanog, Oct3/4, and Sox2 in MDA-MB-231 and MCF7/tamoxifen resistant cells compared with 
MCF7/wild-type. siRNA-mediated Nanog gene silencing can efficiently inhibit cell proliferation 
and induce apoptosis of tamoxifen-resistant breast cancer cells. This study provides a basis for 
further study of the role of Nanog in developing resistance to tamoxifen, its implication in breast 
cancer management, and as a new strategy to enhance response to endocrine therapy.
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Introduction
Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer 
death in women worldwide.1 In the UK, the risk of developing breast cancer is 1 in 8 
 during a female’s lifetime.2 Tamoxifen is the most frequently prescribed drug for treat-
ment of estrogen receptor positive (ER+) breast cancer and to prevent the development 
of breast cancer in women with high risk of developing this  disease.3 Approximately 
70% of breast tumors are ER+; almost 50% of those either fail to respond or to initially 
respond to tamoxifen and eventually become resistant to treatment.4 Resistance to 
tamoxifen is a major clinical challenge in the treatment of breast cancer; however, the 
potential mechanisms of tamoxifen resistance are not fully understood but involve the 
coregulation crosstalk of ER and other signaling pathway networks.5 There is a growing 
body of evidence to support the role of cancer stem cells in tumorigenesis.6 All this 
evidence and these observations in relation to tumor cells and normal stem cells have 
been considered in the cancer stem cell hypotheses, which present a good model of 
self-renewal and pluripotentiality.7
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Studies have shown that small subpopulations of cells are 
present in some tumors such as breast, colon, brain, pancreas, 
prostate, and some other tumor types. This cell fraction is 
defined as cancer stem cells (CSCs), which are characterized 
by their ability to self-renew, to initiate tumors, and to resist 
chemo/radiotherapy.8 Al-Hajj et al have shown that a small 
number of cells with CD44+ and CD24−/low lineage have a high 
ability to initiate a tumor when injected into severe combined 
immunodeficiency (SCID) mice.9 On the other hand, there 
are shared phenotypes between stem cells and cancer stem 
cells regarding the high presence of stemness gene mark-
ers such as Nanog, Sox2, and Oct3/4, which are found to 
be associated with poorly differentiated tumors and with 
high-grade ER− tumors.10 Liu et al reported that the MCF7/
Tmx (tamoxifen transfected) breast cancer cells induce CSC 
properties and may be responsible for tamoxifen resistance 
during breast cancer therapy.11 All this accumulative evidence 
in respect to the links between cancer and stem cells has 
important therapeutic implications. Nanog plays a crucial role 
in sustaining pluripotency in embryonic stem cells (ESCs) 
and promoting self-renewal. It was found to be expressed 
highly in some human tumors such as germ cell tumors and 
breast, cervix, oral cavity, renal, and ovarian carcinomas.12 
However, the actual transcriptional mechanism of Nanog is 
still not clearly understood, but studies have established that 
epigenetic regulators promote Nanog transcription activity, 
whereas other studies indicated direct (positive or negative) 
transcription regulation, and a recent study stated that Nanog 
transcription has its own regulator (auto-regulator).13
The overexpression of Nanog has been used as a predic-
tive factor for tumor progression in colorectal and oral can-
cer.12,14 In cervical cancer, the high expression of cytoplasmic 
Nanog was found to be associated with tumor growth,15 while 
a study by Chambers et al found an association between 
the downregulation of Nanog expression and an increase in 
differentiation tendency in ESCs.16 In breast cancer, Nanog 
gene expression was found to correlate directly with cell 
differentiation.10 Using the MCF7 breast cancer cell line, the 
blocking of Nanog inhibited tumor growth and expansion.12 
Furthermore, data have shown a correlation between Nanog 
expression and stage and treatment prognosis in patients 
with cervical neoplasia. In addition, Nanog was found to 
support the stem-like and immune-resistant phenotype of 
tumor cells through the Akt pathway, which is involved in 
cell survival and apoptosis. Moreover, in the same study, 
Noh et al evaluated the therapeutic implications of Nanog 
via injecting a colorectal cancer cell line (HCT116/SCT-E7) 
into NOD/SCID mice, and then, knocking down the Nanog 
using chitosan nanoparticles, they found that the silencing 
of Nanog enhanced immune-based therapy.17 Hence, a study 
by Shan et al in 2012 of hepatocellular carcinoma indicated 
that the loss of Nanog eliminated the self-renewal ability 
of the human hepatocellular carcinoma cell line, whereas 
the overexpression of Nanog restored this ability.18 Yet, 
the role of Nanog in developing resistance to tamoxifen 
in breast cancer has not been investigated until now. In 
particular, studies have not investigated whether Nanog 
could be a therapeutic target in breast cancer endocrine 
therapy resistance.
Therefore, the aim of this study was to investigate the 
expression of the transcription factors (Nanog, Oct3/4, and 
Sox2) in tamoxifen-resistant breast cancer, provide evidence 
about the role of Nanog in development of tamoxifen resis-
tance in breast cancer, and finally to enhance the response 
to tamoxifen.
Materials and methods
cell lines and cell culture
The ER− breast cancer cell line MDA-MB-231 was purchased 
from European Collection of Cell Cultures (ECACC), and 
MCF7/Tmx and parental MCF7/wild-type were kindly 
donated by Dr Saraswati Sukumar (Johns Hopkins Uni-
versity, Baltimore, MD, USA). All cells were routinely 
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
(Sigma-Aldrich); supplemented with 10% fetal calf serum 
(Sigma-Aldrich), 100 units/mL penicillin-streptomycin, and 
2 mM L-glutamine (Sigma-Aldrich) in a humidified atmo-
sphere of 5% CO
2
 in air at 37°C; and used when the culture 
reached 85%–90% confluence.
Tamoxifen cytotoxicity
Cells were grown in complete DMEM for 48 hours. Then, 
4-hydroxytamoxifen (4-OHT) (Sigma-Aldrich) was dis-
solved in ethanol and added to the culture media to produce 
a range of drug concentrations (1–80 µM), and the cells 
were incubated with the drug for an additional 48 hours. 
Ethanol concentrations added with 4-OHT to the culture 
media were less than 0.3% and had no effect on cell growth 
(viability tested). ED50 values were calculated for each of 
the two tamoxifen-resistant breast cancer cell lines and the 
tamoxifen responsive cell line. Tamoxifen effects were also 
tested in separate experiments in the small interfering RNA 
(siRNA) Nanog-transfected cells to evaluate the growth 
rate and detect the apoptosis. Vehicle treated cells (0.5% 
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v/v ethanol) were always included and were not found to 
affect the results.
Flow cytometric analysis
To measure Nanog, Oct4, and Sox2, cells were fixed in 1 mL 
ice cold methanol (Thermo Fisher Scientific) for 10 minutes 
at −20°C and washed twice in phosphate-buffered saline (PBS) 
1% bovine serum albumin (BSA) (Sigma-Aldrich). Cells were 
then incubated in permeabilization buffer 0.3% Triton X-100 in 
1% BSA (Sigma-Aldrich) at room temperature for 45 minutes. 
Cells were labeled with human Nanog phycoerythrin polyclonal 
antibody goat IgG, human Oct4 MAb mouse IgG and human 
Sox2 monoclonal antibody mouse IgG (R&D System), diluted 
in permeablization solution at a final concentration accord-
ing to the manufacturer’s recommendation and incubated for 
30 minutes at 2°C–8°C. Cells were washed three times by cen-
trifugation at 400× g for 5 minutes and resuspended in ice cold 
PBS. Cells were labeled with appropriate secondary antibody 
diluted in 3% BSA/PBS for 30 minutes at 2°C–8°C in the dark. 
Cells were washed and resuspended in ice cold PBS and 3% 
BSA and immediately analyzed on Epics xL flow cytometer 
(Beckman Coulter, High Wycombe, UK).
sirna transfection
Nanog siRNA was obtained from Life Technologies, UK. 
Breast cancer cell lines were transfected with siRNA 
at concentrations of 1–10 nM using 0.1% (v/v) Lipo-
fectamine RNAiMAX (Life Technologies) according to 
the manufacturer’s instructions. Cell media was changed 
to serum-containing media 24 hours after transfection, and 
cells were maintained in regular culture medium for 48–72 
hours before analysis. Additionally, for each cell line, the 
siRNA was cotransfected into the cells with reporter plas-
mids to assess the efficiency of Nanog knockdown using 
TYE 563M (Origen  Biomedical, Austin, TX, USA) labeled 
transfection control siRNA for each of the transfected cell 
lines and examined using fluorescence microscopy (Nikon, 
Kingston upon Thames, UK).
RT-PCR analysis for siRNA quantification
Reverse transcription polymerase chain reaction (RT-PCR) 
through cyclical amplification was performed to enable 
evaluation of Nanog gene expression prior to and after gene 
silencing. Total RNA was extracted from breast cancer cell 
lines using the RNeasy kit (Life Technologies). At 48 hours 
posttransfection, 1 µg of total RNA was used to synthesize 
cDNA using cDNA kit (Life Technologies) as per manufac-
turer’s instructions. TaqMan gene expression assay kit (Life 
Technologies) reactions were performed using the ABI 7000 
real-time PCR machine, and the experimental cycle threshold 
was calibrated against that of the standard. 
Transfected cell growth rate
Cells were seeded and transfected in a 96-well plate; cell 
growth continued 48 hours from transfection in complete 
media. The wells were then treated with 50 µL of 0.1 mg/mL 
tetrazolium bromide (MTT) (Sigma-Aldrich), the absorbance 
was measured at a wavelength of 570 nm using a microplate 
reader (BMG Labtech, Aylesbury, UK), and the growth 
curves were plotted for each cell line.
Determination of the apoptosis markers 
(Bcl-2 and annexin V) by enzyme-linked 
immunosorbent assay (elisa)
Briefly, Nanog siRNA transfected MDA-MB-231, MCF7/
Tmx, and parental MCF7/WT cells were incubated with 
4-OHT overnight. Cell lysates were prepared, and the level 
of Bcl-2 and annexin V were determined for the treated and 
untreated (control) cells using Bcl-2 and annexin V ELISA.
analysis of Bcl-2 using the quantitative elisa
The human Bcl-2 ELISA kit (eBioscience, Vienna, Austria) 
was used to quantitatively analyze Bcl-2 protein prior to and 
after siRNA transfection in response to 4-OHT. Cells were 
washed twice with PBS and resuspended with lysis buffer for 
60 minutes at room temperature. Cells were recentrifuged and 
resuspended in sample diluent at a ratio of 1:5. Duplication 
of each cell lysate sample and a set of standards in duplicate 
containing serially-diluted (1:2) of lyophilized Bcl-2 standards. 
Biotin-conjugate anti human Bcl-2 monoclonal antibody diluted 
1:100 in the assay buffer were added to each ELISA well and 
incubated for 2 hours at room temperature. Then the assay was 
completed as per manufacturer’s instructions. The absorbance 
of each micro well was then read at 450 nm using an ELISA 
plate reader (BMG LABTECH Ltd., Aylesbury, UK).
analysis of annexin V using the quantitative elisa
Annexin V ELISA kit was purchased from Abnova, Taipei 
City, Taiwan. Standard and negative controls were washed 
thoroughly twice with 400 µL of wash buffer per well. The 
standard dilution and samples were prepared and added to 
the allocated microwells as per manufacturer’s instructions. 
Absorbance was measured at 450 nm using a plate reader 
(BMG Lab Technologies).
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statistical analysis
Data are expressed as the mean ± standard error (SE). 
 Statistically significant differences were determined using 
one-way or two-way analysis of variance, SPSS version 21 
software (IBM). P,0.05 was considered to indicate a statisti-
cally significant result.
Results
cytotoxic effects of tamoxifen
The exposure of cells to 4-OHT induced growth inhibitory 
effects with median ED50 values of 17.5 µM, 25 µM, and 
32 µM for MCF7/WT, MCF7/Tmx, and MDA-MB-231 
respectively.
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Figure 1 Flow cytometric analysis of intracellular staining of embryonic markers (nanog, Oct4, and sox2) in breast cancer cells (McF7/WT, MDa-MB-231, and McF7/Tmx).
Notes: (A–C) cells were labeled using anti-mouse nanog alexa Fluor® 488 antibody, showing 12%, 68%, and 49% positivity in McF7/WT, MDa-MB-231, and McF7/Tmx, 
respectively. (D–F) cells were labeled using goat anti-human Oct4, followed by anti-goat igg secondary antibody showing 14%, 52%, and 55% positivity in McF7/WT, MDa-MB-231 
and McF7/Tmx, respectively. (G–I) cells were labeled using human/mouse sox2 monoclonal antibody, followed by anti-mouse igg secondary antibody, showing 11%, 70%, and 
59% positivity in McF7/WT, MDa-MB-231, and McF7/Tmx, respectively. all the data represent the mean value from three independent experiments (n=3) ± se.
Abbreviations: se, standard error; WT, wild type; Tmx, tamoxifen transfected.
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Figure 2 CT representing the RT-PCR amplifications and the effect of Nanog silencing (siRNA) on the cell growth.
Notes: (A) results of qPcr are expressed as the cT (cycle of threshold) value for each transfected and nontransfected cell line. Data represent the mean value from two 
independent experiments ± se. *P,0.05 indicates significant difference between transfected and nontransfected cell lines. (B) The effects of nanog silencing (sirna) on the growth 
of the cells and response to tamoxifen. results were normalized to viability percentages. The results are an average of three, in duplicate independent experiments (n=3).
Abbreviations: qPcr, quantitative polymerase chain reaction; se, standard error; sirna, small interfering rna; 4-OhT, 4-hydroxytamoxifen; WT, wild-type; Tmx, 
tamoxifen transfected; rT-Pcr, reverse transcription polymerase chain reaction. 
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stemness transcription factor
Stemness protein levels were examined using flow cytometry. 
As shown in Figure 1, positive expression of Nanog, Oct4, 
and Sox2 were observed in tamoxifen-resistant cells MCF7/
Tmx and MDA-MB-231 compared with low expression of 
these factors in parental MCF7/WT.
nanog knockdown inhibits cell 
proliferation and induces apoptosis
Quantitative PCR (qPCR) through cyclical amplification was 
performed to enable quantification of Nanog gene expres-
sion prior to and after siRNA treatment. The experimental 
cycle threshold was calibrated against that of standard and 
all amplifications were performed in duplicate (Figure 2A). 
The effect of Nanog knockdown in combination with 
4-OHT treatment on cells was assessed after monitoring 
for 48 hours (Figure 2B). Data represent mean ± SE of 
three independent experiments (P,0.05); 4-OHT signifi-
cantly inhibits growth in MCF7/Tmx and MDA-MB-231 
in comparison with nontransfected cells. Quantitative 
evaluation of Bcl-2 expression was performed using 
ELISA prior to and after the knockdown of Nanog was 
carried out. Low expression of Bcl-2 was observed in 
the ER− breast cancer cell line MDA-MB-231, and this 
expression increased significantly in response to 4-OHT 
alone (P,0.05) (Figure 3A). In the same way, the siRNA 
transfected MDA-MB-231cell line expressed a slightly 
higher but not significant Bcl-2 level (P.0.05) when cells 
were incubated with 4-OHT. Whereas a high expression of 
Bcl-2 was indicated in the control MCF7/WT cell line and 
this expression reduced after the silencing of the Nanog 
gene and in response to 4-OHT. In contrast, the expres-
sion of Bcl-2 in the MCF7/Tmx breast cancer cell line 
was increased significantly after silencing of the Nanog 
gene (P,0.05). The evaluation of annexin V expression 
was performed by means of ELISA prior to and after the 
knockdown of Nanog. A high expression of annexin V was 
indicated in the tamoxifen responsive cell line MCF7/WT, 
and this expression reduced significantly (P,0.05) when 
the siRNA transfected cells were incubated with 4-OHT 
(Figure 3B). In contrast to the parental MCF7/WT, the 
MCF7/Tmx and MDA-MB-231 cell lines showed a high 
expression of annexin V when the transfected cells were 
incubated with 4-OHT (P,0.05). This expression was 
significantly lower in the control MCF7/Tmx and in the 
non-tamoxifen treated transfected MDA-MB-231 cells.
Discussion and conclusion
Development of resistance to tamoxifen remains an impor-
tant clinical problem. In this study, high expression of 
embryonic markers (Oct4, Sox2, and Nanog) were indicated 
in ER− MDA-MB-231 and MCF7/Tmx, and these expres-
sions were inversely correlated with ER expression and 
response to tamoxifen (Figure 1). In addition, the current 
study showed the key role of Nanog in the development of 
tamoxifen resistance and that reduction in the endogenous 
level of Nanog decreases the proliferation rate and induces 
tamoxifen sensitivity.
A correlation between embryogenesis and oncogenesis 
has become a main subject in the study of cancer biology 
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and therapies, which require the existence of stem/progenitor 
cells that are regulated in response to systemic and local sig-
naling.19,20 Previous studies showed the role of cancer stem 
cells in developing the resistance to therapeutic agents and 
tumor initiation. Based on CD24−/low/CD44+ surface marker 
expression, a population of cancer stem cells has been iso-
lated, characterized by their ability to form tumors in SCID 
mice, even when injected with as few as 200 cells.9 In addi-
tion, the survival of the CD24−/low/CD44+ cancer-initiating 
cells that have been isolated from MCF7 and MDA-MB-231 
breast cancer cells in response to radiation, suggests the role 
of stem/progenitor cells in resistance to therapeutic agents 
and enhancing survival mechanisms.21 Furthermore, there 
are other studies that supported the recent results when the 
response of the subpopulation with CD24−/low/CD44+ to 
chemotherapy was evaluated; these studies found that the 
chemotherapy treatment increases cancer stem cell properties 
after the treatment.22 In line with their findings, our data 
further showed that the expression levels of Oct4, Sox2, and 
Nanog might be simultaneously or individually correlated 
with response to tamoxifen as in MDA-MB-231 and MCF7/
Tmx in comparison with MCF7/WT (Figure 2B).
Nanog has been identified as a transcription factor, and 
its role in maintain self-renewal in ESCs has been established 
in previous studies. Also high expression of Nanog has been 
found to be associated with high pluripotency in ESCs, and 
that Nanog promotes ESC differentiation.23 To know whether 
Nanog participates in the regulation of tamoxifen resistance 
in breast cancer, we performed a Nanog knockdown and then 
measured the growth rate along with apoptosis markers. Results 
revealed an important role of Nanog in regulating growth in 
breast cancer cells. The blocking of Nanog using siRNA showed 
a significant arrest in the growth of the tamoxifen-resistant cells, 
as shown in Figure 2B. This is in agreement with a previous 
study in hepatocellular carcinoma.18 However, there is not a 
clear mechanism to explain the relation between the expression 
of ER and the stemness genes, but CSCs are known to have 
a lack of ER expression; at the same time tamoxifen action is 
dependent on the function of expressed ER.24,25 Therefore, fur-
ther investigation was carried out to evaluate cellular apoptosis. 
Enhancements of apoptosis were indicated after blocking of 
Nanog, suggesting that Nanog might play a relevant role in 
enhancing tamoxifen action, which could be via an alternative 
mechanism, not only via ER dependent mechanisms.25
Knowing that the Bcl-2 family plays an important regula-
tory role in apoptosis, either as activator (Bax) or as inhibitor 
(Bcl-2), interestingly, in this study, the MCF7/WT expressed a 
high level of Bcl-2 in comparison with both resistant (MCF7/
Tmx and MDA-MB-231) cell lines (Figure 3A). This is in 
agreement with a previous clinical study published by  Daidone 
et al,26 who showed an association between the overexpression 
of Bcl-2 and ER expression along with other biologic features 
of a differentiated phenotype such as slow proliferation, pro-
gesterone receptor expression, and human epidermal growth 
factor receptor 2 (Her2) expression. Also, this study found 
that women with ER+ and Bcl-2− breast cancer have worse 
prognoses than those with ER− and Bcl-2+ breast cancer.26 
Furthermore, the high expression of Bcl-2 could be related to 
the lack of caspase 3  expression.27 As it is not clear why Bcl-2 
represents a molecular marker for better prognosis in breast 
cancer, the cell death was quantified using annexin V ELISA 
to determine the real implication of the siRNA on response 
to tamoxifen (Figure 3B). A low expression of annexin V was 
indicated in the tamoxifen-resistant cell line, and this expres-
sion increased when cells were treated with a combination 
of siRNA Nanog and 4-OHT, indicating an enhancement of 
apoptosis.
A previous study of tamoxifen cytotoxicity showed that 
annexin V expression in response to tamoxifen is time- and 
dose-dependent, that there is a peak value, and that soon after 
that, the expression reduces sharply in ER− breast cancer cells. 
This might explain the significant expression of annexin V in 
MDA-MB-231 breast cancer cells when treated with 4-OHT 
and the lack of a significant increase in expression of annexin 
V in MCF7/WT. This atypical expression of annexin V as 
reported in a previous study is mainly caused by the irregular 
expression of associated caspase 3 in response to tamoxifen.28 
However, that may not be a full and accurate explanation of 
the low expression of annexin V in siRNA MDA-MB-231 
cells or in siRNA and 4-OHT treatment of MCF7/WT and 
could be related to the deregulation of Nanog and its effect on 
the apoptosis and cell cycle arrest. Further study is needed to 
find out the effects of the stemness gene in the regulation of 
apoptosis and how that reflects on the presence and absence of 
caspase 3, 8, and 9. In addition, further studies could include 
DNA fragmentation to indicate early and late apoptosis and 
secondary necrosis.
In addition, another study showed that tamoxifen could 
mediate its apoptosis effects via activation of the caspase 3 
pathway in ER− breast cancer cells.29 These previous studies 
in both ER+ and ER− breast cancer cells are in agreement 
with the finding in the study reported here. At the same time, 
the expression of Bcl-2 increased in both resistant cell lines 
(Figure 3A), which is in agreement with previous studies that 
identified an association between the expression of Bcl-2 and 
ER status, with improved survival from breast cancer.30 Also, 
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it has been reported that ERα influenced the survival of breast 
cancer cells through regulation of Bcl-2/Bax.31
In a parallel experiment, quantitative expression of 
annexin V was determined by ELISA after 48 hours of 
interference with siRNA Nanog. As shown in Figure 3B, 
the combination of siRNA Nanog and 4-OHT caused an 
increase in expression of annexin V in MDA-MB-231 and 
MCF7/Tmx cells. In contrast, this expression was reduced in 
ER+ MCF-7 cells significantly. The results confirmed that the 
blocking of Nanog was very effective in inducing apoptosis 
in ER− MDA-MB-231 and MCF7/Tmx cells, whereas it had 
no effect in MCF7/WT cells.
However, the mechanism of tamoxifen resistance is 
still not fully understood, but it is known that tamoxifen’s 
effect depends on the expression of ER; mainly, the devel-
opment of tamoxifen resistance is associated with a loss 
of ER.32 The current results showed that the lack of ER in 
the MDA-MB-231 cell line was correlated with positive 
core transcription factor expression. This correlation was 
still significant in the acquired tamoxifen-resistant cell line 
MCF7/Tmx in comparison with the parental MCF7/WT. 
These results might indicate an inverse correlation between 
the cancer stem cells and the expression of ER, which might 
explain the resistance to tamoxifen.24,33 The results from 
this study indicated that the role of Nanog is not limited 
to the development of tumorigenesis only, but also plays a 
role in the development of resistance to tamoxifen, and it 
is inversely correlated with ER expression and apoptosis. 
The implication of this finding is that a combination of 
tamoxifen and Nanog interference could be developed as 
a new treatment to enhance response to tamoxifen and to 
induce apoptosis.
However, the expression of annexin V was not detected 
in MCF7 cells in response to siRNA and 4-OHT; this sug-
gests that in MCF7 cells there may be another mechanism 
of apoptosis, which could be a caspase 3 independent 
pathway. There are many studies dealing with apoptosis 
in MCF7 in response to different therapeutic agents. 
All studies show DNA fragmentation despite the lack of 
caspase 3,34 or apoptosis could be because of the effect 
of tamoxifen on Bcl-2 expression. A study by Zhang et al 
showed that the downregulation of Bcl-2 correlated with 
tamoxifen-induced apoptosis, and this is in agreement with 
the current results of the expression of Bcl-2 and annexin 
V in MCF7/WT.35 However, any findings different from 
the current results could be due to the differences in the 
variants of MCF7 cells used,36 because the results for the 
Bcl-2 and annexin V expression showed a clear significant 
effect of the siRNA Nanog on the expression of the Bcl-2 
and apoptosis (annexin V) in MDA-MB-231 and MCF7/
Tmx breast cancer cells. Further study of DNA fragmen-
tation and the effects of Nanog on caspase 3, 6, 7, and 9 
expression will be useful.
The results from this study indicated that the role of 
Nanog is not limited to the development of tumorigenesis 
only, but Nanog also has a role in the development of resis-
tance to tamoxifen, and it is inversely correlated with ER 
expression and the apoptosis pathway. The results are in 
agreement with a recent study published by Piva et al that 
shows that the silencing of the Sox2 gene in ER− breast cancer 
reduced the size of the stem/progenitor cell population and 
restored response to tamoxifen treatment.37
The implication of this finding is that a combination of 
tamoxifen and Nanog interference could be developed as 
new treatment to enhance the response to tamoxifen and to 
induce apoptosis.
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